1. Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition)
- Author
-
Xian-Tao Zeng, Ying-Hui Jin, Tong-Zu Liu, Fang-Ming Chen, De-Gang Ding, Meng Fu, Xin-Quan Gu, Bang-Min Han, Xing Huang, Zhi Hou, Wan-Li Hu, Xin-Li Kang, Gong-Hui Li, Jian-Xing Li, Pei-Jun Li, Chao-Zhao Liang, Xiu-Heng Liu, Zhi-Yu Liu, Chun-Xiao Liu, Jiu-Min Liu, Guang-Heng Luo, Yi Luo, Wei-Jun Qin, Jian-Hong Qiu, Jian-Xin Qiu, Xue-Jun Shang, Ben-Kang Shi, Fa Sun, Guo-Xiang Tian, Ye Tian, Feng Wang, Yin-Huai Wang, Yu-Jie Wang, Zhi-Ping Wang, Zhong Wang, Qiang Wei, Min-Hui Xiao, Wan-Hai Xu, Fa-Xian Yi, Chao-Yang Zhu, Qian-Yuan Zhuang, Li-Qun Zhou, Xiao-Feng Zou, Nian-Zeng Xing, Da-Lin He, Xing-Huan Wang, the Chinese Urological Doctor Association (CUDA), Urological Association of Chinese Research Hospital Association (CRHA-UA), and Uro-Health Promotive Association of China International Exchange and Promotive Association for Medical and Health Care (CPAM-UHPA)
- Subjects
Transurethral plasmakinetic resection of prostate ,Benign prostatic hyperplasia ,Recommendation ,Treatment ,Guideline ,Medicine (General) ,R5-920 ,Military Science - Abstract
Abstract Benign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different populations incorporating the efficacy and safety of TUPKP in the treatment of normal volume (
- Published
- 2022
- Full Text
- View/download PDF